Page 170 - Haematologica Vol. 109 - July 2024

ARTICLE - MAIC in 3L+ FL
M.J. Maurer et al.
declares consulting or advisory role (BeiGene, ADCT, Lilly, As- traZeneca, Janssen, Genentech, Inc., HutchMed, Kite/Gilead); research funding (Genentech, Inc., Celgene, Novartis, Takeda, AstraZeneca, Loxo/Lilly, Lam Therapuetics, BioInvent); Expert Testimony (Hawaii). BSK declares consultancy (Astrazeneca, ADCT Therapeutics, Roche, Genetech, Abbvie, MEI, Acerta- Pharma,Pharmacyclics, Celgene/BMS, Beigene, Kite, Janssen, Incyte, Hutchmed, TG Therapeutics, BeiGene, Genmab, Seat- tle Genetics); research funding (Genetech, Abbvie, Celgene/ BMS, BeiGene Astra Zeneca, Hutchmed); speaker’s bureau (Research to Practice). JLK declares consulting or advisory role (Gamida Cell, MorphoSys, BeiGene USA, TG Therapeutics); research funding (Viracta Therapeutics). YM declares current employment (Genentech/Roche); stock ownership (Genen- tech/Roche). AM declares current holder of individual stocks in a privately-held company (Roche); current holder of stock options in a privately-held company (Roche). MCW declares current employment (Genentech); stock ownership (Roche); travel, accommodation, and expenses (Genentech/Roche). AS declares current employment (F. Hoffmann-La Roche Ltd.); stock ownership (F. Hoffmann-La Roche Ltd). JL declares stock ownership (F. Hoffmann-La Roche Ltd.). JC declares consulting or advisory role (BMS, Protagonist Therapeutics SMC). BKL declares consulting or advisory role (Genentech/ Roche, MEI Pharma Inc.); research funding (Genentich/Roche, Genmab, Celgene, AstraZeneca); expert testimony (Amgen). CRF declares consulting or advisory role (Bayer, Gilead, Spec- trum Pharmaceuticals, AbbVie, Celgene, Denovo Biopharma, BeiGene, Karyopharm Therapeutics, Pharmacyclics/Janssen, Genentech/Roche, Epizyme, Genmab, Seattle Genetics, Fore-
References
1. Jacobsen E. Follicular lymphoma: 2023 update on diagnosis and management. Am J Hematol. 2022;97(12):1638-1651.
2. Sarkozy C, Maurer MJ, Link BK, et al. Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts. J Clin Oncol. 2019;37(2):144-152.
3. Qualls D, Salles G. Prospects in the management of patients with follicular lymphoma beyond first-line therapy. Haematologica. 2022;107(1):19-34.
4. Link BK, Day BM, Zhou X, et al. Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study. Br J Haematol. 2019;184(4):660-663.
5. Rivas-Delgado A, Magnano L, Moreno-Velázquez M, et al. Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era. Br J Haematol. 2019;184(5):753-759.
6. Batlevi CL, Sha F, Alperovich A, et al. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J. 2020;10(7):74.
7. Salles G, Schuster SJ, Fischer L, et al. A retrospective cohort study of treatment outcomes of adult patients with relapsed or refractory follicular lymphoma (ReCORD-FL). Hemasphere.
sight Diagnostics, BMS, Curio Science, AstraZeneca, Mor- phoSys); stock ownership (Foresight Diagnostics, N Power); research funding (Acerta Pharma, Janssen, Gilead, Celgene, TG Therapeutics, Genentech/Roche, Pharmacyclics, AbbVie, Millennium, Alimera Sciences, Xencor, 4D Pharma, Adaptim- mune, Amgen, Bayer, Cellectis, EMD Serono, Guardant Health, Iovance Biotherapeutics, Kite/Gilead, MorphoSys, Nektar, Novartis, Pfizer, Sanofi, Takeda, Ziopharm Oncology). WRB has no conflicts of interest to disclose.
Contributions
MM, CC, ML, JL, TH, IL, YW, LN, CS, DC, PM, JC, BK, WB, JK, YM, AM, MW, MCW, AS, JL, JC, BL and CF are responsible for the conception and/or design of the study/research, for analysis and/or interpretation of the data, and wrote the manuscript. MM, CC, ML, JL, TH, IL, YW, LN, CS, DC, PM, JC, BK, WB, JK, JC, BL and CF are responsible for the collection and/or assembly of the data.
Funding
This work was supported by a grant from the National Cancer Institute: Lymphoma Epidemiology of Outcomes (U01CA195568) and a research grant from Genentech. No medical writer was used for this manuscript.
Data-sharing statement
The data in the study are not publicly available. Data sharing policies and the process to request the LEO CReWE data that support the findings of this study can be found on the LEO Cohort website: https://leocohort.org/
2022;6(7):e745.
8. Budde LE, Sehn LH, Matasar M, et al. Safety and efficacy of
mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022;23(8):1055-1065.
9. Casulo C, Larson MC, Lunde JJ, et al. Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study. Lancet Haematol. 2022;9(4):e289-e300.
10. Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15(6):940-947.
11. Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Making. 2018;38(2):200-211.
12. Albarmawi H, Nagarajan M, Onukwugha E, et al. Follicular lymphoma treatment patterns between 2000 and 2014: a SEER-Medicare analysis of elderly patients. Future Oncol. 2020;16(8):353-365.
13. Xie C, Li R, Huang X, Chihara D, Flowers CR. The impact of
Haematologica | 109 July 2024
2184